公开(公告)号：US20210346441A1

公开(公告)日：2021-11-11

申请号：US17382146

申请日：2021-07-21

Applicant: CELVERUM, INC.

Inventor： David Conrad ,  Cory Batenchuk ,  Fabrice Leboeuf ,  John Cameron Bell

IPC: A61K35/766 ,  C12N7/00 ,  A61K45/06 ,  C07K14/005 ,  C12N7/04 ,  C12N7/06 ,  A61P35/02

Abstract: There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.

公开(公告)号：US11110138B2

公开(公告)日：2021-09-07

申请号：US14654259

申请日：2013-12-20

Applicant: CELVERUM INC.

Inventor： David Conrad ,  Cory Batenchuk ,  Fabrice Leboeuf ,  John Cameron Bell

IPC: C12N7/04 ,  C12N7/06 ,  C07K14/00 ,  A61K35/766 ,  C12N7/00 ,  A61K45/06 ,  C07K14/005 ,  A61P35/02 ,  A01N63/00

Abstract: There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.

公开(公告)号：US09623096B2

公开(公告)日：2017-04-18

申请号：US13672190

申请日：2012-11-08

Applicant: Celverum Inc.

Inventor： David Conrad ,  John Cameron Bell ,  Harry Atkins

IPC: A61K39/00 ,  C12N5/09

CPC classification number: A61K39/0011 ,  A61K2039/5152 ,  A61K2039/5156 ,  C12N5/0693 ,  C12N5/0694 ,  C12N2510/00 ,  C12N2760/20032 ,  C12N2770/36032

Abstract: An immunogenic formulation for a patient, the formulation includes virus-modulated hematopoietic cancer cells, where the modulated hematopoietic cancer cells are generated from viable hematopoietic cancer cells obtained from the patient, either isolated or in a mixed hematopoietic population of healthy and cancer cells, and where the viable hematopoietic cancer cells are infected ex vivo with a virus that modulates the expression of a plurality of endogenous immune regulatory molecules to increase the immunogenicity of the hematopoietic cancer cells.